THE REMARKS

The Amendment

Claims 1-2, 6-11, and 16-17 are cancelled as drawn to non-elected claims.

Claim 20 is amended to depend on Claim 4. Applicants have carefully reviewed the compounds of Claim 20 and delete all of the non-elected compounds in Claim 20. In addition, Claim 20 is amended to correct minor typographic errors as follows:

[2-(3,5-Difluoro-phenyl)-acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide is amended to 2-[(3,5-Difluoro-phenyl)-acetylamino]-N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-propionamide.

2-[2'-(3,5-Difluorophenyl)-2'-hydroxyacetylamino]-*N*-[5-(1-methyl-1- phenylethyl)-2*H*-pyrazol-3-yl]-propionamide is amended to 2-[2-(3,5-Difluorophenyl)-2-hydroxyacetylamino]-*N*-[5-(1-methyl-1- phenylethyl)-2*H*-pyrazol-3-yl]-propionamide.

2-[2'-(3,5-Difluorophenyl)-2'-hydroxyacetylamino]-N-[5-[1-2,3-difluorophenyl)-1-methylethyl]-2H- pyrazol-3-yl]-propionamide is amended to <math>2-[2-(3,5-Difluorophenyl)-2-hydroxyacetylamino]-N-[5-[1-2,3-difluorophenyl)-1-methylethyl]-2H- pyrazol-3-yl]-propionamide.

No new matter is added in any of the amendments.

Telephone Interview with the Examiner

Applicants thank Examiner Shameem for the telephone interview dated January 25, 2010. During the interview, Examiner indicated that Claims 4, 13-15 and 19 were allowable, and Claims 3, 5, 12, and 18 were rejoinable and allowable. Applicants agreed to cancel the non-elected Claims 1, 2, 6-11 and 16-17. Applicants also proposed that Claim 20 would be amended to depend on Claim 4 and to delete the non-elected compounds. Examiner agreed to consider the amended Claim 20.

CONCLUSION

Applicants believe that the application is in good and proper condition for allowance. Early notification of allowance is earnestly solicited.

Date: February 8, 2010 Respectfully submitted,

Viola T. Kung, Ph.D. (Reg No. 41,131)

Howrey LLP 2941 Fairview Park Drive, Suite 200 Falls Church, VA 22042 Telephone: 650-798-3570

Fax: 650-798-3600